<DOC>
	<DOCNO>NCT00006656</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness carmustine treat patient progressive recurrent glioblastoma multiforme .</brief_summary>
	<brief_title>Carmustine Treating Patients With Progressive Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose intratumoral carmustine ethanol ( DTI-015 ) patient unresectable recurrent glioblastoma multiforme . ( Phase I study close accrual 01/15/2002 . ) - Determine qualitative quantitative toxicity regimen patient . - Assess activity regimen patient . - Estimate peripheral blood carmustine level patient treat regimen . OUTLINE : This dose-escalation , multicenter study . Patients receive carmustine ethanol ( DTI-015 ) intratumorally 5 minute stereotactic biopsy open craniotomy . Cohorts 3-6 patient receive escalate dos DTI-015 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose-limiting toxicity . ( Phase I study close accrual 01/15/2002 . ) Additional patient receive treatment DTI-015 recommend phase II dose . Patients follow 4 , 8 , 12 week every 1-3 month disease progression . PROJECTED ACCRUAL : A total 12 patient accrued phase I study approximately 14-18 patient accrue phase II study . ( Phase I study close accrual 01/15/2002 . )</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove supratentorial malignant glioblastoma multiforme Clear evidence disease progression MRI Unresectable tumor spherical , spheroid , ovoid shape ( multicentric multilobulated ) Central necrosis and/or central cystic area allow presence enhance rim thickness great 5 mm No brainstem ( pons medulla ) midbrain ( mesencephalon ) involvement No involvement primary sensorimotor cortex dominant hemisphere within 1.5 cm optic chiasm , either optic nerve , cranial nerve No tumor extension ventricular system Tumor volume great 33.4 cm3 At least one prior radiotherapy PATIENT CHARACTERISTICS : Age : 18 75 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No evidence bleed diathesis Hepatic : Bilirubin great 2.0 mg/dL SGOT/SGPT great 2.5 time normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 40 mL/min BUN great 30 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active uncontrolled infection Afebrile unless fever due presence tumor No concurrent serious medical psychiatric illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin include Gliadel wafer therapy ) recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No prior intracranial brachytherapy Surgery : Recovered prior surgery Other : No prior anticoagulants No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>